PTGX: Protagonist Therapeutics Inc

PTGX新闻

• 15:07 TD Cowen维持对Protagonist Therapeutics的买入评级，将目标价上调至160美元
• 15:07 TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160
• 15:00 Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
• 14:01 Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
• 13:47 UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184
• 12:53 Leerink Partners 将 Protagonist Therapeutics 评级上调至“跑赢大盘”，并将目标价上调至 190 美元
• 12:53 Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190
• 13:10 Johnson & Johnson: Strong Catalysts, But I’m Staying At Hold (NYSE:JNJ)
• 14:45 10年前投资Protagonist Therapeutics的100美元今天会变成多少
• 14:45 Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
• 09:30 The Peptide Boom That Isn’t About Your Muscles
• 13:05 J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
• 19:27 Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
• 12:58 Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday - Apple (NASDAQ:AAPL), Robinhood Markets (NA
• 19:54 Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
• 16:38 Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)
• 14:38 J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead